Cyto-KIK: A phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib).

Karie Runcie,Eric A. Singer,Moshe Chaim Ornstein,Christopher B. Anderson,Matthew Dallos,Jessica Hawley,Emerson A. Lim,Charles G. Drake,Benjamin Izar,Hiram A. Shaish,Mark N. Stein

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 2|浏览6

暂无评分

摘要

TPS371Background: Despite recent therapeutic advancements in metastatic renal cell carcinoma (mRCC), only 5-10% of patients will achieve a complete response (CR) to therapy. Cytoreductive nephrecto...

查看译文

关键词

kidney cancer,cytoreductive surgery,kinase inhibition,cabozantinib,cyto-kik

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要